Regulation and Prequalification

Regulation and Prequalification

 

The Department of Regulation and Prequalification (RPQ), within the WHO Health Systems, Access and Data Division, supports Member States in building robust, resilient and reliable regulatory systems and ensures that quality‑assured medicines, vaccines, diagnostics and other health products are available to populations in need.

RPQ’s work is grounded in two core functions:

  • strengthening national and regional regulatory systems and promoting reliance to improve oversight of health products and technologies; and
  • prequalifying essential health products for use in countries that have not yet established a robust, resilient and reliable regulatory authority and rely on WHO’s assessments to guide procurement and regulatory decision‑making.

Robust regulatory systems are critical to safeguarding the quality, safety and performance of health products throughout their entire lifecycle from development and assessment to post‑market surveillance. Where such systems are not yet fully established, WHO plays a unique and indispensable role.

The RPQ Department draws on extensive global expertise through advisory groups, technical networks, the WHO Coalition of Interested Parties, WHO collaborating centres and a wide range of partners. 

Featured

Publications

All →
Report of the joint meeting of ACSoMP and GACVS June 2026

The Global Advisory Committee on Vaccine Safety (GACVS) was established in 1999, and the Advisory Committee on Safety of Medicinal Products (ACSoMP) was...

Vaccines, thiomersal and autism spectrum disorder: evidence review 2010-2025

This systematic review provides a current assessment of peer-reviewed studies published between 2010 and August 2025 investigating potential associations...

Towards a greener pharmaceuticals' regulatory highway: a framework for regulators as enablers of decarbonization

This framework provides a roadmap for how pharmaceutical regulatory systems can support innovation that reduces the climate impact of medicines for human...

WHO Drug Information - Volume 40, No. 2

The second issue of volume 40 for 2026 includes:- Evidence-to-Decision Framework to Prioritize PD-1 and PD-L1 Immune Checkpoint Inhibitors for the WHO...

Related health topics